Therapeutic effect of ARBs on insulin resistance and liver injury in ptients with NAFLD and chronic hepatitis C: A pilot study

Munechika Enjoji, Kazuhiro Kotoh, Masaki Kato, Nobito Higuchi, Motoyuki Kohjima, Manabu Nakashima, Makoto Nakamuta

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Fatty liver is one of the local morphological manifestations of metabolic syndrome and is frequently associated with insulin resistance. Insulin resistance is also common in patients with chronic hepatitis C. Hyperinsulinemia is an independent risk factor for hypertension and cardiovascular mortality. The aim of this study was to evaluate the therapeutic efficacy of angiotensin II receptor blockers (ARBs), telmisartan and olmesartan, for patients with non-alcoholic fatty liver disease (NAFLD) and chronic hepatitis C (CH-C). We analyzed the incidence of obesity, insulin resistance, and other disorders in patients with NAFLD (Group A), CH-C (Group B), or other liver diseases (Group C). We evaluated whether the ARBs, telmisartan and olmesartan, improved insulin resistance and liver injury by measuring the homeostasis model assessment ratio of insulin resistance (HOMA-IR) and serum alanine aminotransferase (ALT). The incidence of obesity (BMI ≥25 kg/m2) was significantly higher in Group A than in Groups B and C. The incidence of insulin resistance (HOMA-IR ≥22.5) in Groups A and B was significantly higher than in Group C. Regular doses of telmisartan and olmesartan significantly improved HOMA-IR and ALT levels not only in NAFLD patients but also in patients with CH-C. The effects tended to be more notable with telmisartan. In conclusion, telmisartan and olmesartan improved insulin sensitivity and may possibly be used as liver protecting agents in CH-C as well as NAFLD patients.

Original languageEnglish
Pages (from-to)521-527
Number of pages7
JournalInternational journal of molecular medicine
Volume22
Issue number4
DOIs
Publication statusPublished - Oct 1 2008

Fingerprint

Angiotensin Receptor Antagonists
Therapeutic Uses
Chronic Hepatitis C
Insulin Resistance
Liver
Wounds and Injuries
Homeostasis
Alanine Transaminase
Incidence
Obesity
Non-alcoholic Fatty Liver Disease
Hyperinsulinism
Fatty Liver
Liver Diseases
telmisartan
Hypertension
Mortality
olmesartan

All Science Journal Classification (ASJC) codes

  • Genetics

Cite this

Therapeutic effect of ARBs on insulin resistance and liver injury in ptients with NAFLD and chronic hepatitis C : A pilot study. / Enjoji, Munechika; Kotoh, Kazuhiro; Kato, Masaki; Higuchi, Nobito; Kohjima, Motoyuki; Nakashima, Manabu; Nakamuta, Makoto.

In: International journal of molecular medicine, Vol. 22, No. 4, 01.10.2008, p. 521-527.

Research output: Contribution to journalArticle

Enjoji, Munechika ; Kotoh, Kazuhiro ; Kato, Masaki ; Higuchi, Nobito ; Kohjima, Motoyuki ; Nakashima, Manabu ; Nakamuta, Makoto. / Therapeutic effect of ARBs on insulin resistance and liver injury in ptients with NAFLD and chronic hepatitis C : A pilot study. In: International journal of molecular medicine. 2008 ; Vol. 22, No. 4. pp. 521-527.
@article{1a534c94aeac4851ad25627750596d1a,
title = "Therapeutic effect of ARBs on insulin resistance and liver injury in ptients with NAFLD and chronic hepatitis C: A pilot study",
abstract = "Fatty liver is one of the local morphological manifestations of metabolic syndrome and is frequently associated with insulin resistance. Insulin resistance is also common in patients with chronic hepatitis C. Hyperinsulinemia is an independent risk factor for hypertension and cardiovascular mortality. The aim of this study was to evaluate the therapeutic efficacy of angiotensin II receptor blockers (ARBs), telmisartan and olmesartan, for patients with non-alcoholic fatty liver disease (NAFLD) and chronic hepatitis C (CH-C). We analyzed the incidence of obesity, insulin resistance, and other disorders in patients with NAFLD (Group A), CH-C (Group B), or other liver diseases (Group C). We evaluated whether the ARBs, telmisartan and olmesartan, improved insulin resistance and liver injury by measuring the homeostasis model assessment ratio of insulin resistance (HOMA-IR) and serum alanine aminotransferase (ALT). The incidence of obesity (BMI ≥25 kg/m2) was significantly higher in Group A than in Groups B and C. The incidence of insulin resistance (HOMA-IR ≥22.5) in Groups A and B was significantly higher than in Group C. Regular doses of telmisartan and olmesartan significantly improved HOMA-IR and ALT levels not only in NAFLD patients but also in patients with CH-C. The effects tended to be more notable with telmisartan. In conclusion, telmisartan and olmesartan improved insulin sensitivity and may possibly be used as liver protecting agents in CH-C as well as NAFLD patients.",
author = "Munechika Enjoji and Kazuhiro Kotoh and Masaki Kato and Nobito Higuchi and Motoyuki Kohjima and Manabu Nakashima and Makoto Nakamuta",
year = "2008",
month = "10",
day = "1",
doi = "10.3892/ijmm_00000051",
language = "English",
volume = "22",
pages = "521--527",
journal = "International Journal of Molecular Medicine",
issn = "1107-3756",
publisher = "Spandidos Publications",
number = "4",

}

TY - JOUR

T1 - Therapeutic effect of ARBs on insulin resistance and liver injury in ptients with NAFLD and chronic hepatitis C

T2 - A pilot study

AU - Enjoji, Munechika

AU - Kotoh, Kazuhiro

AU - Kato, Masaki

AU - Higuchi, Nobito

AU - Kohjima, Motoyuki

AU - Nakashima, Manabu

AU - Nakamuta, Makoto

PY - 2008/10/1

Y1 - 2008/10/1

N2 - Fatty liver is one of the local morphological manifestations of metabolic syndrome and is frequently associated with insulin resistance. Insulin resistance is also common in patients with chronic hepatitis C. Hyperinsulinemia is an independent risk factor for hypertension and cardiovascular mortality. The aim of this study was to evaluate the therapeutic efficacy of angiotensin II receptor blockers (ARBs), telmisartan and olmesartan, for patients with non-alcoholic fatty liver disease (NAFLD) and chronic hepatitis C (CH-C). We analyzed the incidence of obesity, insulin resistance, and other disorders in patients with NAFLD (Group A), CH-C (Group B), or other liver diseases (Group C). We evaluated whether the ARBs, telmisartan and olmesartan, improved insulin resistance and liver injury by measuring the homeostasis model assessment ratio of insulin resistance (HOMA-IR) and serum alanine aminotransferase (ALT). The incidence of obesity (BMI ≥25 kg/m2) was significantly higher in Group A than in Groups B and C. The incidence of insulin resistance (HOMA-IR ≥22.5) in Groups A and B was significantly higher than in Group C. Regular doses of telmisartan and olmesartan significantly improved HOMA-IR and ALT levels not only in NAFLD patients but also in patients with CH-C. The effects tended to be more notable with telmisartan. In conclusion, telmisartan and olmesartan improved insulin sensitivity and may possibly be used as liver protecting agents in CH-C as well as NAFLD patients.

AB - Fatty liver is one of the local morphological manifestations of metabolic syndrome and is frequently associated with insulin resistance. Insulin resistance is also common in patients with chronic hepatitis C. Hyperinsulinemia is an independent risk factor for hypertension and cardiovascular mortality. The aim of this study was to evaluate the therapeutic efficacy of angiotensin II receptor blockers (ARBs), telmisartan and olmesartan, for patients with non-alcoholic fatty liver disease (NAFLD) and chronic hepatitis C (CH-C). We analyzed the incidence of obesity, insulin resistance, and other disorders in patients with NAFLD (Group A), CH-C (Group B), or other liver diseases (Group C). We evaluated whether the ARBs, telmisartan and olmesartan, improved insulin resistance and liver injury by measuring the homeostasis model assessment ratio of insulin resistance (HOMA-IR) and serum alanine aminotransferase (ALT). The incidence of obesity (BMI ≥25 kg/m2) was significantly higher in Group A than in Groups B and C. The incidence of insulin resistance (HOMA-IR ≥22.5) in Groups A and B was significantly higher than in Group C. Regular doses of telmisartan and olmesartan significantly improved HOMA-IR and ALT levels not only in NAFLD patients but also in patients with CH-C. The effects tended to be more notable with telmisartan. In conclusion, telmisartan and olmesartan improved insulin sensitivity and may possibly be used as liver protecting agents in CH-C as well as NAFLD patients.

UR - http://www.scopus.com/inward/record.url?scp=54049086556&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=54049086556&partnerID=8YFLogxK

U2 - 10.3892/ijmm_00000051

DO - 10.3892/ijmm_00000051

M3 - Article

C2 - 18813860

AN - SCOPUS:54049086556

VL - 22

SP - 521

EP - 527

JO - International Journal of Molecular Medicine

JF - International Journal of Molecular Medicine

SN - 1107-3756

IS - 4

ER -